Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06160310 · ClinicalTrials.gov registry record
Tuberous Sclerosis Complex and Lymphangioleiomyomatosis Pregnancy Registry (TSC-LAM Registry)
A clinical trial of Lymphangioleiomyomatosis and Tuberous Sclerosis Complex, sponsored by David M. Ritter.
- Recruiting
- Registry status
- 300
- Enrollment target
- 1
- Study location
NCT06160310 is a study of Lymphangioleiomyomatosis and Tuberous Sclerosis Complex that is actively recruiting participants, run by David M. Ritter. The registered enrollment target is 300 participants, below the 800-participant average among 10 other Lymphangioleiomyomatosis trials with a reported enrollment target (62% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06160310, a study of Lymphangioleiomyomatosis and Tuberous Sclerosis Complex, is actively recruiting participants, sponsored by David M. Ritter.
- RECRUITING
- Registry status
- 300 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is an observational registry designed to gather information about Tuberous Sclerosis Complex (TSC) and Lymphangioleiomyomatosis (LAM) in pregnant women and their child.
Conditions Studied
Study Locations (1)
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2023-07-01 |
| Est. Completion | 2029-07-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06160310
The ClinicalTrials.gov registry entry for NCT06160310 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 800-participant average among 10 other Lymphangioleiomyomatosis trials with a reported enrollment target (62% lower). The listed sponsor is David M. Ritter, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Lymphangioleiomyomatosis appearing as the primary indexed condition, and to 0 interventions.
NCT06160310 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT06160310 about?
NCT06160310 is a clinical study titled "Tuberous Sclerosis Complex and Lymphangioleiomyomatosis Pregnancy Registry (TSC-LAM Registry)". This study is an observational registry designed to gather information about Tuberous Sclerosis Complex (TSC) and Lymphangioleiomyomatosis (LAM) in pregnant women and their child.
What is the current status of trial NCT06160310?
This trial is currently recruiting. The enrollment target is 300 participants. The study started on 2023-07-01. Estimated completion is 2029-07-01.
What conditions does trial NCT06160310 study?
This clinical trial studies the following conditions: Lymphangioleiomyomatosis, Tuberous Sclerosis Complex.
Who is sponsoring clinical trial NCT06160310?
This trial is sponsored by David M. Ritter, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06160310 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphangioleiomyomatosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Nebulized or Inhaled Albuterol for Lymphangioleiomyomatosis
RECRUITING · Phase 1
-
Safety and Durability of Sirolimus for Treatment of LAM
RECRUITING
-
TSC Biosample Repository and Natural History Database
RECRUITING
-
Evaluating the Long-term Safety and Tolerability of Imatinib in Patients With Lymphangioleiomyomatosis (LAM)
RECRUITING · Phase 1
-
Study of the Disease Process of Lymphangioleiomyomatosis
RECRUITING
-
Feasibility of [11C]Acetate-PET in LAM and TSC
ACTIVE NOT RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.